ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib (BMS-354825) was designed by Bristol-Myers Squibb and Otskuka Pharmaceutical Co., Ltd. to inhibit imatinib resistant BCR-ABL mutations in CML but it also works against Src family kinases [255,256,257,258].